REFRACTORY OVARIAN CARCINOMA
Clinical trials for REFRACTORY OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
Disease control Recruiting nowThis Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combinatio…
Matched conditions: REFRACTORY OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Ira Winer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Supercharged immune cells take on tough ovarian cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with ovarian cancer that has returned or is resistant to standard platinum chemotherapy. The treatment uses a patient's own immune cells (T cells), which are trained in a lab to recognize and attack a protein called MUC1 fou…
Matched conditions: REFRACTORY OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for tough ovarian cancer: CBX-12 trial launches
Disease control Recruiting nowThis study tests a new drug, CBX-12, in 40 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if CBX-12 can shrink tumors and how safe it is at two different dose levels given every three weeks. Participants must have a specif…
Matched conditions: REFRACTORY OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC